Janux Therapeutics Return on Equity

Janux Therapeutics (JANX) currently reports a ROE of -15.8%. That is below the Healthcare sector average of 21.67%. Use the charts on this page to explore Janux Therapeutics's ROE history and peer comparisons.

Janux Therapeutics's ROE of -15.8% is lower than the Healthcare sector average of 21.67%. That is roughly 172.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Janux Therapeutics's current -15.8% should be judged against Healthcare norms (sector average: 21.67%) and against JANX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -15.8%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.67%. From there, open related valuation or income-statement pages for Janux Therapeutics, and consider following JANX for alerts when major investors trade the stock.

Janux Therapeutics is classified in the Healthcare sector. On ROE, it currently shows -15.8% versus a sector average near 21.67%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing JANX with unrelated industries.